Chris Womack | AMiner学者主页

Sarah A. Loddick, Sarah J. Ross, Andrew G. Thomason, David M. Robinson, Graeme E. Walker, Tom P.J. Dunkley,Sandra R. Brave, Nicola Broadbent, Natalie C. Stratton,Dawn Trueman,Elizabeth Mouchet, Fadhel S. Shaheen,

2023

引用

AI阅读

9Supplementary Figure 3-7 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Theresa A. Proia,Maneesh Singh,Richard Woessner,Larissa Carnevalli,Gayathri Bommakanti,Lukasz Magiera,Srimathi Srinivasan,Shaun Grosskurth,Mike Collins,Chris Womack,Matthew Griffin,Minwei Ye,

Syngeneic mouse tumor efficacy, STAT3, and gene expression changes

2023

引用

AI阅读

10Supplementary Methods from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Theresa A. Proia,Maneesh Singh,Richard Woessner,Larissa Carnevalli,Gayathri Bommakanti,Lukasz Magiera,Srimathi Srinivasan,Shaun Grosskurth,Mike Collins,Chris Womack,Matthew Griffin,Minwei Ye,

Gating and antibodies for flow cytometry and CyTOF

2023

引用

AI阅读

11Supplementary Figure 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 145K, Isoform specificity of PI3Kbeta antibody (AGG4888).

2023

引用

AI阅读

12Supplementary Table 1 from Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma

Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca P.A. Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,

PDF file - 57K, Clinicopathological features of TMA Set 1.

2023

引用

AI阅读

13Supplementary Table 2 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Theresa A. Proia,Maneesh Singh,Richard Woessner,Larissa Carnevalli,Gayathri Bommakanti,Lukasz Magiera,Srimathi Srinivasan,Shaun Grosskurth,Mike Collins,Chris Womack,Matthew Griffin,Minwei Ye,

Patient tumor gene expression data

2023

引用

AI阅读

14Supplementary Figures 1 -7 from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function in Vitro and in Vivo

Sarah A. Loddick,Sarah J. Ross,Andrew G. Thomason,David M. Robinson,Graeme E. Walker,Tom P.J. Dunkley,Sandra R. Brave,Nicola Broadbent,Natalie C. Stratton,Dawn Trueman,Elizabeth Mouchet,Fadhel S. Shaheen,

PDF - 464KB, Supplementary Figure 1: Inhibition of AR transcripts with AZD3514 treated LNCaPs in steroid free media and the timecourse of AZD3514 effects in the presence and absence of DHT. Supplementary Figure 2: Effect of AZD3514 on growth of AR negative cells. Supplementary Figure 3: AR and PSA expression in LAPC4 cells treated with AZD3514. Supplementary Figure 4: AR degradation and synthesis rates of a C-terminal AR peptide, as measured by Mass Spectrometry. Supplementary Figure 5: Comparison of ARD1 & AZD3514 effects on seminal vesicle weight in rats, and pharmacokinetic effects in mice and rats Supplementary Figure 6: Effect of ARD1 on growth and AR in the HID28 model. Supplementary Figure 7: Dose response effects of AZD3514 on AR nuclear translocation and foci formation.

2023

引用

AI阅读

15Supplementary Figures 10 and 11 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1